key: cord-0302471-qobuzheu
authors: Cantera, Jason L.; Lillis, Lorraine M.; Peck, Roger B.; Moreau, Emmanuel; Schouten, James A.; Davis, Paul; Drain, Paul K.; Andama, Alfred; Pinter, Abraham; Kawasaki, Masanori; Källenius, Gunilla; Sundling, Christopher; Dobos, Karen M.; Flores, Danara; Chatterjee, Delphi; Murphy, Eileen; Halas, Olivia R.; Boyle, David S.
title: Performance of novel antibodies for lipoarabinomannan to develop diagnostic tests for Mycobacterium tuberculosis
date: 2022-04-12
journal: bioRxiv
DOI: 10.1101/2022.04.12.488063
sha: 169d3d12060892630c68d3866c64611f93c97b64
doc_id: 302471
cord_uid: qobuzheu

Lipoarabinomannan (LAM), a component of the Mycobacterium tuberculosis (MTB) cell wall, is detectable in the urine of MTB infected patients with active tuberculosis (TB). LAM-specific antibodies (Igs) have been developed by a variety of traditional and recombinant methods for potential use in a rapid diagnostic test (RDT). We evaluated the analytical performance of the TB LAM Igs to identify pairs that offer superior performance over existing urine LAM tests. We assessed 25 new and 4 existing Igs in a matrixed format using a multiplex electrochemiluminescence-based liquid immunoassay. A total of 841 paired Ig combinations were challenged with in vitro cultured LAM (cLAM) derived from MTB strains representing diverse phylogenetic lineages, alongside urinary LAM (uLAM) from the urine of adults with active pulmonary TB. Analytical sensitivity of down-selected Ig pairs was determined using MTB Aoyama-B cLAM, while diagnostic accuracy was determined using clinical samples. When testing cLAM, the reactivity of Ig pairs was similar across MTB lineages 1-4 but lineage 5:6 had significantly more reactivity among Ig pairs. Overall, 41 Ig pairs had a strong binding affinity to cLAM, as compared to the reference pair of S4-20/A194-01, and 28 Ig pairs therein exhibited a strong affinity for both cLAM and uLAM. Retrospective testing on clinical urine specimens demonstrated varying sensitivities (12-80%) and specificities (14-100%). The five top pairs had a similar analytical limit of detection to the reference pair but in four instances, the sensitivity and specificity with clinical uLAM samples was poor. Overall, epitopes presented by uLAM are different from cLAM, which may affect antibody performance when testing uLAM in patient samples. Several new Ig pairs had similar ranges of high sensitivity to cLAM but overall, there were no new candidate Ig pairs identified in this round of screening with increased performance with uLAM as compared to an existing optimal pair.

Aoyama-B cLAM, while diagnostic accuracy was determined using clinical samples. When testing cLAM, 33 the reactivity of Ig pairs was similar across MTB lineages 1-4 but lineage 5:6 had significantly more 34 reactivity among Ig pairs. Overall, 41 Ig pairs had a strong binding affinity to cLAM, as compared to the 35 reference pair of S4-20/A194-01, and 28 Ig pairs therein exhibited a strong affinity for both cLAM and 36 Introduction suspected cases of TB (17) (18) (19) (20) . These factors make urinary LAM (uLAM) a candidate biomarker for a rapid 67 antigen TB test (21) . The terminal end of LAM has structural domains that present immunologic epitopes 68 including at least one TB specific target (12, 22, 23) , and uLAM is present in all active TB cases regardless 69 of the anatomical site(s) of disease. 70

Recent advances to increase the sensitivity of LAM immunoassays have focused on developing 71

Igs with improved sensitivity and specificity to TB LAM (22-26), sample preparation including pre-72 treatment to remove confounders (27) (28) (29) , pre-enrichment of uLAM from urine prior to testing (30, 31) , 73 amplifying the stripe signal (32) or highly sensitive immunoassay platforms (33-35). Our aim was to 74 assess the analytical performance of TB LAM antibodies (Igs) to identify pairs that offer superior 75 performance over existing urine LAM tests. We applied the MesoScale Diagnostic (MSD) immunoassay 76 platform to interrogate 25 new Igs targeting LAM epitopes in both capture and detector positions in 77 comparison to reference Igs previously screened on this platform (33). The optimal candidates were 78 down selected based on their initial performance with cultured LAM from six different lineages of MTB 79 and clinical uLAM, and the best in class then assessed for their limit of detection and performance with a 80 light and heavy chain sequences from other candidate anti-LAM Igs to create new Igs and Fab forms of 90

Igs. These materials were generated from a variety of TB LAM antigen sources including purified LAM 91 from in vitro cultured MTB cells, inactivated in vitro cultured MTB cells, synthetic glycans to specific TB 92 LAM epitopes and the creation of recombinant forms prepared from memory B cells collected from 93 convalescent TB patients (22 Each Ig was labeled to serve in the capture and detector positions, respectively. Each Ig was 124 then assessed using a sandwich immunoassay format hosted on a highly sensitive multiplex instrument 125 creating a total of 841 Ig pairs that were compared for their ability to detect LAM. Per their protocols, 126 two aliquots of each antibody (1 mg/mL) were labelled with biotin (EZ-Link Sulfo-NHS-LC-Biotinylation 127

Kit, ThermoFisher Scientific, Waltham, MA, USA) for the capture position and SULFO-TAG (GOLD SULFO-128

The biotinylated capture Igs were coupled to U-PLEX plates (MSD) via biotin-streptavidin binding 137 to U-PLEX linkers (MSD). To prepare the capture component of the antibody array, up to 10 antibody-138 linker conjugates were combined in U-PLEX stop buffer at a concentration of 0.29 µg/mL per antibody, 139 and 50 µL of this pooled mixture was added to individual well of each plate. The plates were incubated 140 for 1 hour with shaking at 500 rpm to allow the antibody array to self-assemble to the complimentary 141 antibody linker-binding sites on the bottom of the U-PLEX plate. Unbound material was removed by 142 washing 3 times with 300 µL/well of phosphate buffered saline + 0.05% Tween 20 (PBS-T, pH 7.5) using a 143

BioTek 405 TS microplate washer (BioTek Instruments Inc., Winooski, VT, USA). 144

Firstly, 25 µL of Buffer 22 (MSD) was added to each well in the plate before adding 25 µL of 145 either cLAM or clinical specimens. Appropriate dilutions of cLAM were prepared in PBS + 1% BSA. The 146 plates were incubated by shaking at 500 rpm for 1 hour at room temperature. Plates were washed 3 147 times with PBS-T and then 25 µL of 2 µg/mL SULFO-TAG detection antibody in Diluent 3 (MSD) was 148 added to each well, and then incubated by shaking at 500 rpm for 1 hour at room temperature. Plates 149 were then washed 3 times to remove excess detection reagent, and each well filled with 150 µL of 2X 150 read buffer T (MSD). The plates were read by MESO QuickPlex SQ 120 plate reader (MSD) and the ECL 151 from each individual array spot was subsequently measured using the Discovery Workbench v4 software 152 (MSD). 153

The Ig pair S4-20/ A194-01 (capture/detector) was used as the reference pair (33) and to which 154 each of the array spots in each well representing different capture Igs was compared. The signal-to-155 noise ratio (S/N) of the reference pair was expressed as 100% and each of the array spots in each plate 156 expressed as percentile of this value. When serial dilutions of the Aoyama-B LAM were used to generate 157 a calibration curve, the relationship of ECL to TB LAM concentration was fitted to a four-parameter 158 logistic (4-PL) function. The limit of detection (LoD) was calculated from the fitted curve. Other parameters used for down-selection included signal of blank/background (ideally ECL <500), and 172 that the signal with cLAM and uLAM (ECL >10,000 at 5 ng/mL). Next, the best in class Ig pair candidates 173 were evaluated using 7-point dilutions of the Aoyama-B LAM in 1% BSA in PBS (ranging from 40,000 to 174 0.016 pg/mL) in duplicate. Ig pairs were ranked in terms of their respective limit of detection (LoD). 175

Finally, the optimal pairs were evaluated for their ability to detect uLAM in 16 clinical urine specimens 176 collected from 4 geographical regions (Peru, South Africa, Vietnam, and Uganda). 177 178 Results 179 A total of 841 Ig pairs were interrogated and compared for their ability to detect LAM. Each pair 180 was interrogated using 5 ng/mL of in vitro cLAM antigen per test, which is the mid-range concentration 181 used in the 7-point LAM calibration curve. The cLAM from MTB lineages was used to investigate if any of candidates were pairs with a signal intensity of 90% or greater as compared to the reference pair; the 184 pooled S/N data is shown in Table 2 . The signal-minus-noise (S-N) data from lineage 1 had two capture 185 candidates (5E3 and 1E9) that were greater than the reference pair; these were both paired with A194-186 01 giving values of 109% and 118%, respectively (S1 Table) . Scoring these with S/N, there were 9 pairs 187 that had a score of ≥90% (Table 2; S2 Table) . The highest percentile scores were with MCD024 Fab 188 (266%) and MCD024 Fab2 (173%) when paired with A194-01 as detector. When using S4-20 as the Table) . Here, the pair 5E3/S4-20 gave 99% and the other Igs each used A194-01 as the 204 detector. The capture Igs were MCD022 Fab (112%), FDX-01 (121%), 1E7 (157%) and 5E3 (224%). When 205 S/N was applied the number of candidates increased to 11 pairs but conversely none of the S-N 206 candidates in the screen were observed when S/N was applied (Table 2, S6 Table) . The increase in pairs was observed with S4-20 primarily being the detector included A194-01 (91%), MCD024 Fab2 (93%), S4-208 20 (95%), FDX-01 (104%), BJ-03(117%), MCD022 Fab2 (132%), BJ-76 (150%), 1E7 (207%) and 5E3 (279%). 209

Two pairs with A194-01 as detector were >90%, MCD024 Fab2 (186%) and MCD024 Fab (216%). The S-N 210 data for lineage 4 was very similar to lineage 1 with two only pairs, 1E7/A194-01 (104%) and 5E3/A194-211 01 (133%) were more reactive than the RAP (S7 Table) . Using S/N there were 12 pairs that were scored 212 (Table 2; S8 Table) . Two with an A194-01 detector, MCD024 Fab and MCD024 Fab2 produced scores of 213 Table) . Using S/N, the lineage 5:6 gave the greatest number of more reactive Ig pairs with 29 221 pairs (excluding the RAP) overall being identified with four new Igs as the detector but all detector Igs 222 having been previously observed with the other lineages (Table 2, S10 Table) . There were BJ-76, BTM-1, 223 MCD024 Fab and MCD024 Fab2. BJ-76 worked well in the capture position with 5 pairs being identified 224 as opposed to just one with lineages 2-4. The use of S4-20 as the detector was also interesting in that it 225 produced 14 pairs including the three that had the highest S/N ration in the entire set; BJ-06/S4-20 226 (734%), 5E3/S4-20 (746%), 1E7/S4-20 (753%) ( Table 2) . Overall, the data from lineages 1-4 were highly 227 similar with A194-01 and S4-20 being the primary detectors with KI24 a sole addition for lineage 1. As 228 noted, MTB lineage 5:6 is interesting in that a greater number of pairs were reactive, however the other 229

Igs observed to be reactive across all of the lineages were also captured in this set. The S-N and S/N data 230 from each lineage were pooled into one set (Table 2, S11 and S12 Tables) and the pairs with the highest S/N compared to the lineage specific pairs (Table 2) . Here only A194-01 and S4-20 were consistently 232 observed as the best detectors. With A194-01 there were only two capture Igs that were scored highly 233 out with the reference control pair. These were MCD024 Fab (175%) and MCD024 Fab2 (166%) which 234 are both recombinant forms derived from A194-01 recognizing Ara4, Ara6 ± Man1 cap and 1E7 and 5E3 235 also recognize a similar Ara4, Ara6 epitope (Table 1) interesting to note that the MTX cap recognized by S4-20 (Table 1) Table  251 1). Other Igs that had relatively better performance included 5E3 and 1E7 (7/74 [9.5%] and 6/74 [8.1%]), 252 these are both recombinant forms that target the Ara4 and Ara6 termini. Interestingly, FDX-01 a 253 recombinant form of FIND28 was found in 4 pairs while FIND28 was isolated only in one, both Igs Screening Ig performance with uLAM. Alternative structural modifications to LAM are thought to occur 256 during in vivo culture of MTB (e.g. uLAM) and an understanding of the structural differences between in 257 vivo and in vitro derived LAM is still very limited (36,37). One study on infected mouse lung tissue 258 suggests the succinylation of the Ara4 residue in the arabinan terminal motif and that Man caps and 259

terminal Ara motifs may be altered or cleaved in cLAM wherein uLAM had a decrease in the terminal Ara 260 motif and Man caps while the Ara 5 termini increased (37). In light of this proposed variance, the set of 261 841 Ig pairs were screened using uLAM via a single sample of urine to interrogate the performance of 262 each Ig pair via the percentiles of the S-N and S/N ratios as compared to the RAP (S4-20/A194-01; Table  263 3, S13 and S14 Tables). The S/N ratios were again used to identify candidates with elevated values. 264 Table 3 . A heat map of the normalized S/N from anti-LAM Ig pairs that were most reactive to 266 urinary LAM from a clinical sample. All highlighted data points shown are percentiles of S/N with 267 ≥90% of the output from the reference assay Ig pair (RAP, 100%) . Capture Igs are in the vertical 268 column and detector Igs in the horizontal row. Unfilled boxes represent samples with an S/N 269 ratio of ≤89% as compared to the RAP). and MCD022Fab2). The most significant change observed was that S4-20, the best performing detector 282 candidate with the cLAM antigen, was now seen in only one highly reactive Ig pair when challenged with 283 uLAM. Conversely, A194-01 was a poorer performer with cLAM but now performed as the best detector 284 Ig for uLAM with 10/34 (29.4%) of the most reactive Ig pairs. In the capture Ig position there were 12 285 candidates, of which 3 represented over 50% of all the Ig pairs (FDX-01, FIND28 and MCD022 Fab [ Table  286 3]). FDX-01 is a recombinant form of FIND28 and so it is unsurprising that both Igs exhibited similar 287 performance in recognizing the epitopes (8/34 and 6/34 pairs respectively). However, MCD022 Fab (4/34 pairs), is an rAb derived from S4-20 and so it is unusual that the parent performed less well (Table  289 3). 290

Overall, 10 Ig pairs exhibited higher S/N ratios than the reference pair using cLAM prepared 291 from different MTB lineages as the antigen (Table 3 , Tables S1-S10), while there are 34 Ig pairs with 292 higher S/N ratio than the reference pair when using uLAM (see Table 3, Table S12 ). These Ig pairs were 293 pooled and ranked based upon their ECL signal intensities as observed when assaying both cLAM and 294 uLAM samples (See Lineage and uLAM data folder in Dataverse file); an ECL of ≥10,000 was the 295 threshold for strong positives, while the ECL threshold for background intensity was 500 (5X greater 296 than the reference pair). In total, 28 Ig pairs were identified with 13 capture and 6 detector Igs with 1E7, 297 A194-01, MCD022 Fab, and MCD022Fab2 being the only Igs that were present in both configurations 298 (see Table 4 The Ig pairs exhibited a range of LoDs spanning from 256.6 pg/mL (FIND28/KI24) to the lowest at 313 3.3 pg/mL (the reference pair, S4-20/A194-01). However, a further 12 Ig pairs had an LoD of ≤10 pg/mL. 314 Therefore, while none of the new candidates in this assessment had a better analytical senstivity than 315 the reference assay when using Aoyoma B cLAM, there are a variety of other Ig pairs with similar levels 316 of performance. Within these Igs pairs there were no clear best in class but the epitopes recognized 317 were roughly split with 7 capture Igs targeting Ara4 or Ara6 or Ara4, Ara6 termini (Table 4 ). With the 318 detector Ig, it was close between Igs A194-01 (8 pairs) and S4-20 (9 pairs) for detector . The epitopes 319 recognized here are either Ara4, Ara6 ± Man1 cap or a MTX ± Man cap, respectively. 320

The performance of the 28 Ig pairs were compared on a panel of 16 clinical samples from 321 confirmed TB positive and negative cases and for participants who were also diagnosed as HIV positive 322 or negative. The diagnostic sensitivity and specificity were calculated for each pair from the clinical data 323 (molecular and culture diagnosis). When using sensitivity as the key metric, the S4-20/A194-01 pair was 324 again best in class at 90%. Four other pairs had a sensitivity of 80% with each using A194-01 as the 325 detector (Table 4 ). The associated capture antibodies were MCD024 Fab, FIND28, BJ-076 and FDX-01. 326

When a further 8 clinical samples were screened with these 5 pairs the sensitivity improved for each of 327 them but with the order of ranking not changing. However, when specificity was also assessed the 328 performance of the top 5 pairs became varied. The ranking changed slightly with MCD024 Fab/A194-01 329 having 100% specificity while S4-20/A194-01, was next at 84%. The MTX motif recognized by S4-20, 330 MCD024 Fab and BJ-76 is unique to MTB and yet BJ-76 was more indiscriminate in its binding with a 331 specificity of 56% as opposed to S4-20 and MCD024 Fab. addition to the small sample volume (60 L) that limits the sensitive detection of uLAM (e.g. <250 349 pg/mL). We aimed to identify candidate Ig pairs from new antibody development efforts to improve the 350 sensitivity of rapid antigen assays targeting uLAM. We accessed a range of Igs, in addition to their 351 derivatives as Fabs from the light and heavy chain variable regions. The immunogens used were whole 352 A highly versatile microarray platform enabled the rapid screening of 841 candidate pairs in 355 both the detection and candidate orientations using a variety of epitopes to equivocally assess 356 performance. Overall, the results from these rounds of screening did not identify any new candidate Igs 357 with better performance. Somewhat surprisingly given the number of LAM Igs pairings assessed, the 358 reference pair S4-20/A194-01, remained the best overall candidate. Recombinant derivatives of A194-01 359

were assessed and while reaching the top tier after three rounds of screening they did not perform as 360 well as the original candidates with uLAM. This may be attributed to subtle structural changes when 361 expressed with a different core antibody structure or lost performance with events such as misfolding 362 during production that can significantly affect performance (43). 363

An interesting outcome of this work was the demonstration that some Ig pairs each had good 364 performance when using cLAM antigen derived from in vitro cultured TB cells but their performance on 365 uLAM samples was poorer. This suggests that uLAM may have structural differences from cLAM which is 366 a homogenous and relatively pure material. However, uLAM is generated from in vivo culture in the host 367 and there is preliminary evidence of structural differences with succinylation and a higher prevalence of 368 Ara 5 and a profound lack of Ara6 in the urine of a HIV-ve/TB +ve subject (19,37). We speculate that 369 there are opportunities for modification of uLAM termini via enzymatic or physiochemical decay 370 removing the MTX-1, Man caps or Ara termini as shown with an increase of Ara5 in uLAM (37). The 371 heterogeneity of uLAM means that the detailed composition and structure of uLAM remains unresolved 372 as compared to cLAM. Other compounds found in urine may also affect Ig binding via the masking of 373 epitopes by proteins or other materials sequestering them or other compounds binding to the Igs, 374 rendering them non-or partially functional. Despite the considerable amount of effort in generating Igs 375 to LAM to date, until their screening is focused on performance assessments using uLAM sources, Igs 376 resulting in improved performance are unlikely to be found. We used cLAM from MTB strains representing 6 different lineages in our screening process and 378 with four lineages observed little difference and with the 5-6 lineage many more Ig pairs were reactive. 379

This suggests that some epitopes may be more accessible in this lineage to but overall the majority of 380 these Ig pairs then performed poorly with uLAM. In looking at development of the Igs used in this study, 381 the majority (19) used cLAM or whole TB cells as the immunogen. As such, if novel structural LAM 382 epitopes are created only by in vivo cultured cells then these potential epitopes will be missed and 383 conversely, if recombinant Igs are screened from the memory B cell population of convalescent TB 384 patients (e.g. A194-01, (22)), using cLAM as the target antigen in screening may miss Igs targeting uLAM 385 epitopes not present in cLAM. Ig development efforts using synthetic glycans to generate Igs to the TB 386 specific MTX-1 motif, targeted by S4-20 (23) did not produce a successful product but highlight the 387 potential for targeted Ig generation to epitopes. Using glycan arrays has played a key role in 388 understanding which LAM epitopes are targeted by the antibody candidates to date (22). 389

Our study had a range of limitations. Firstly, screening with cLAM may not find the most suitable 390

Igs that target uLAM. Our initial hypothesis was that screening with multiple TB lineages may identify 391 some key structural differences in LAM that could be reflected by different Ig pairs having improved 392 performance on specific lineages (36). As noted we did not see appreciable differences between 393 lineages and using cLAM from one lineage for further down select only selected for those Igs that had 394 better performance with cLAM. As such, a larger sample set of antibody pairs should have been 395 screened on more urine samples to identify if the initial screens using cLAM was inadequate. Our uLAM 396 samples, while reflecting geographic diversity, were very small in terms of their number. A further study 397 will focus on fewer Igs using significantly greater numbers of urine samples. A further perspective is the 398 nature of the assay used for screening. A liquid immunoassay works optimally with Igs that have slower 399 on rate kinetics as the Igs have sufficient time to recognize and bind to their target epitopes. In a rapid 400 antigen test, the exposure time of the antibody to its target is likely a few seconds at most and so the kinetics of what binds best are different from a liquid immunoassay. A recent study compared a subset 402 of Ig pairs in this work (289 pairs) via detection of Aoyoma-B cLAM on the MSD platform versus an LFA 403 screening platform (30). In comparing signal outputs from both methods, they showed a weak positive 404 correlation, with R values of 0.30 (p < 0.0001) and 0.36 (p < 0.0001) for S-N and S/N. New Igs continue 405 to be produced, some taking novel approaches using camelid sources to develop Igs that can recognize 406 smaller antigen targets. FIND hosts a biorepository with multiple urine samples for developers to access 407 and PATH recently developed a method to purify and enrich up to 50% of the total uLAM from urine for 408 early screening of antibody development candidates (44). These efforts in conjunction with ongoing 409 innovations in sample enrichment, assay design, and signal amplification may result in the affordable 410 and effective rapid antigen test that is so urgently needed to identify TB cases and offer them entry into 411 the cascade of care for a curable disease. 412 Acknowledgements 414 We are most grateful to the consented participants who gave the urine samples from the study cohorts 415 in Ghana, Peru, South Africa, and Vietnam. We greatly appreciate the work from the staff at the 416 Makerere University (Uganda) in collecting and processing the urine specimens and the support of Dr. 

Location, location, location: tuberculosis services in highest burden 437 countries

Structural features of lipoarabinomannan 472 from Mycobacterium bovis BCG. Determination of molecular mass by laser desorption mass 473 spectrometry

Exosomes released from macrophages 475 infected with intracellular pathogens stimulate a proinflammatory response in vitro and in vivo

Exosomes carrying mycobacterial antigens can protect mice against

Mycobacterium tuberculosis infection

Estimation of D-Arabinose by Gas 480

Chromatography/Mass Spectrometry as Surrogate for Mycobacterial Lipoarabinomannan in

Lipoarabinomannan 483 binding to lactosylceramide in lipid rafts is essential for the phagocytosis of mycobacteria by 484 human neutrophils

Rapid diagnosis of 486 tuberculosis by detection of mycobacterial lipoarabinomannan in urine

Lipoarabinomannan in 493 sputum to detect bacterial load and treatment response in patients with pulmonary tuberculosis: 494 Analytic validation and evaluation in two cohorts

A sensitive urinary 496 lipoarabinomannan test for tuberculosis

A mycobacterial 498 lipoarabinomannan specific monoclonal antibody and its F(ab') fragment prolong survival of mice 499 infected with Mycobacterium tuberculosis

Generation of monoclonal 501 antibodies to the specific sugar epitopes of Mycobacterium avium complex serovars

SpeClean: urine sample treatment method for ultra-sensitive LAM diagnostics

50th Union World Conference on Lung Health